Alzheimer's disease (AD). However, the mechanisms that link disruption of the blood-brain barrier (BBB) to neurodegeneration are poorly understood, and exploration of fibrin as a therapeutic target has been limited by its beneficial clotting functions. Here we report the generation of monoclonal antibody 5B8, targeted against the cryptic fibrin epitope γ 377-395 , to selectively inhibit fibrin-induced inflammation and oxidative stress without interfering with clotting. 5B8 suppressed fibrin-induced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation and the expression of proinflammatory genes. In animal models of MS and AD, 5B8 entered the CNS and bound to parenchymal fibrin, and its therapeutic administration reduced the activation of innate immunity and neurodegeneration. Thus, fibrin-targeting immunotherapy inhibited autoimmunity-and amyloid-driven neurotoxicity and might have clinical benefit without globally suppressing innate immunity or interfering with coagulation in diverse neurological diseases.
A ctivation of innate immunity is a key feature of neurological diseases with different etiologies, including autoimmune and neurodegenerative CNS diseases 1 . Increasing evidence indicates that pathogenic activation of CNS innate immunity contributes to neuronal damage and modulates the onset and progression of neurodegenerative diseases 2 . Oxidative injury and release of free radicals have been proposed as common mechanisms for innate immunity-driven neurodegeneration and demyelination in MS and AD [3] [4] [5] [6] . Chronic activation of innate immunity and oxidative injury are key elements that drive neurodegeneration in both relapsing-remitting MS and progressive MS 3, 7, 8 . In progressive MS, there is robust microglial activation, oxidative stress and neurodegeneration 3, 8, 9 . Pathogenic activation of innate immunity contributes to oxidative stress and cognitive decline in AD 5 . Little is known about the pathogenic signals that activate innate immune cells toward neurotoxic phenotypes. Understanding the mechanisms of the activation of CNS innate immunity is essential for deciphering how neuroinflammation contributes to neuronal damage and for designing treatments for the selective suppression of pathogenic functions of innate immunity.
The activation of innate immunity, disruption of the BBB and deposition of fibrin are intimately linked in neurological diseases 10, 11 . The blood-coagulation factor fibrinogen extravasates into the CNS parenchyma after disruption of the BBB and is converted into insoluble fibrin, a key proinflammatory matrix that activates innate immune responses 11, 12 . The conversion of fibrinogen into fibrin exposes amino acids 377-395 in the fibrinogen γ -chain (γ [377] [378] [379] [380] [381] [382] [383] [384] [385] [386] [387] [388] [389] [390] [391] [392] [393] [394] [395] ) that bind to the CD11b I-domain of the CD11b-CD18 integrin receptor (also known as Mac-1, complement receptor 3 (CR3), or α M β 2 ) and induces the activation of microglia and macrophages [13] [14] [15] [16] . Fibrin is deposited in AD and MS lesions at sites of microglial activation and macrophage infiltration (reviewed in ref. 11 ). Fibrin is detected in progressive MS and in active and chronic lesions (reviewed in ref. 11 ). In progressive MS, deposition of fibrin in the cortex correlates with neuronal loss and inhibition of fibrinolysis 17 . Disruption of the BBB and deposition of fibrin also occur early in MS and precede demyelination 18, 19 . Fibrinogen has been proposed as a cerebrospinal fluid and plasma biomarker for AD and mild cognitive impairment, and increased concentrations of fibrinogen are considered a predictor of brain atrophy in AD (reviewed in refs 11, 20 ) . Depletion of fibrin
Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration
Articles NATure IMMuNology either genetically in fibrinogen-deficient mice or by anticoagulants decreases neuroinflammation, demyelination and axonal damage in animal models of MS and reduces the activation of microglia, damage to white matter and cognitive decline in animal models of AD (reviewed in ref. 11 ). Fibrin induces rapid and sustained microglial responses and infiltration of macrophages into the CNS 15, 16 . Although increased disruption of the BBB and deposition of fibrin correlate with neurodegeneration, the molecular links between the leakage of blood into the CNS and neuronal damage are poorly understood. Furthermore, whether and how fibrin-induced activation of innate immunity is neurotoxic remains largely unknown.
Here we report an unanticipated role for fibrin as an activator of the NADPH oxidase complex that induced the release of reactive oxygen species (ROS) and innate immunity-driven neurotoxicity in autoimmunity-and amyloid-driven neurodegeneration. Although activation of innate immunity is an attractive candidate for therapeutic intervention, selective therapies that inhibit the neurotoxic effects of innate immune responses are not widely available. By targeting the cryptic fibrin epitope γ 377-395 , we developed the first, to our knowledge, fibrin-targeting immunotherapy (monoclonal antibody 5B8) that selectively targets the inflammatory form of fibrin without interfering with clotting or the activation of innate immune cells by other ligands, such as lipopolysaccharide (LPS). 5B8 selectively bound to fibrin, but not to soluble fibrinogen, and inhibited binding of fibrin to CR3 without interfering with fibrin polymerization, in vivo clotting time or activated partial thromboplastin time (aPTT) in human plasma. 5B8 reduced the activation of NADPH oxidase, the release of ROS, the activation of microglia and neurodegeneration in animal models of MS and AD. These studies identify fibrin as a blood-derived signal that activates NADPH oxidase to promote innate immunity-driven neurotoxicity and identify fibrin-targeted immunotherapy as a novel therapeutic strategy that suppresses innate immunity-driven neurodegeneration at sites of increased vascular permeability without interfering with clotting or globally suppressing innate immunity.
Results
Design of fibrin-targeting immunotherapy. The carboxyl terminus of the fibrinogen γ -chain contains two distinct non-overlapping sites at γ 400-411 and γ 377-395 , which mediate platelet engagement and inflammation, respectively ( Fig. 1a ). Peptide γ 400-411 is the binding site for the platelet integrin receptor α IIb β 3 and is required for platelet aggregation. Peptide γ 377-395 is the binding site for the CD11b I-domain of CD11b-CD18 14 and is required for fibrin-induced activation of microglia and macrophages 13, 15, 16 . The binding site γ 377-395 is considered 'cryptic' in the soluble fibrinogen molecule and is exposed only after the conversion of fibrinogen to insoluble fibrin 14 (Fig. 1a ). We hypothesized that monoclonal antibodies to γ 377-395 would selectively recognize fibrin and inhibit fibrin's interaction with the CD11b I-domain without affecting blood coagulation. To control for CD11b I-domain-binding specificity, we also generated mouse monoclonal antibodies to the fibrin epitope γ 190-202 , which is also cryptic but is not required for binding to the CD11b I-domain 14 .
Using a streamlined screening strategy, we selected monoclonal antibodies that selectively bound fibrin and inhibited the activation of microglia ( Supplementary Fig. 1a ). Antibodies 5B8, 4E11 and 4F1 had the greatest selectivity and specificity for γ 377-395 , while antibody 1E3, directed against γ 190-202 , did not bind γ 377-395, as expected ( Fig. 1b and Supplementary Fig. 1b ). To discriminate between fibrinogen and fibrin in biochemical and cellular assays, we developed an in vitro fibrin substrate that bound to a recombinant CD11b I-domain more strongly than fibrinogen did ( Supplementary Fig. 1c ), which suggested exposure of the γ 377-395 epitope in vitro. All antibodies to cryptic epitopes bound with higher affinity to fibrin than to fibrinogen; among antibodies targeting γ 377-395 , 5B8 bound fibrin to the greatest degree, with minimal binding to soluble fibrinogen ( Fig. 1c and Supplementary Fig. 1d ). Competitive binding assays showed that 5B8 bound to human and mouse γ 377-395 peptides but not to γ 190-202 peptide ( Supplementary Fig. 1e ). 5B8 inhibited binding of the CD11b I-domain to fibrin ( Fig. 1d ), which suggested that 5B8 interfered with the ligand-receptor interaction.
Fibrin activates microglia, as indicated by morphological activation characterized by an increase in cell size that is also associated with gene-expression changes 13, 16 . An assay of morphological activation, combined with automated quantification, was suitable for an unbiased and rapid comparison of multiple fibrin-targeting antibody clones in primary microglial cultures. Notably, among all antibodies generated against cryptic epitopes, only antibodies to γ 377-395 inhibited fibrin-induced morphological activation of microglia; the greatest inhibition (~87%) was by 5B8 ( Supplementary  Fig. 2a ). Antibody 1E3, directed against γ 190-202 , also bound fibrin but did not inhibit microglial activation ( Supplementary  Fig. 2a ), suggesting that inhibition of fibrin's proinflammatory functions depends on targeting γ 377-395 . The F(ab) fragment of 5B8 also inhibited fibrin-induced microglial activation ( Supplementary  Fig. 2b ). 5B8 inhibited fibrin-induced morphological microglial activation in a concentration-dependent manner and reduced the expression of genes encoding proinflammatory molecules ( Fig.  1e and Supplementary Fig. 2c,d ). The isotype-matched control antibody IgG2b, with endotoxin concentrations of < 0.002 EU/μ g ( Supplementary Fig. 2e ), was used as control for all experiments in the study. 5B8 did not alter the polymerization of fibrinogen into fibrin, did not inhibit the aPTT in human plasma and had no effect on the clotting time of mouse plasma in vivo ( Fig. 1f-h ). ~80% of 5B8 was recovered 5 d after a single intraperitoneal injection into healthy wild-type mice ( Supplementary Fig. 2f ), which suggested that 5B8's preferential binding to fibrin and minimal binding to soluble fibrinogen resulted in a minimal sink effect.
In microglia and macrophages, fibrin induces the expression of genes encoding proinflammatory molecules associated with immune responses and cell recruitment 16 . In bone marrow-derived macrophages (BMDMs), 5B8 reduced the fibrin-induced transcriptional activation of genes encoding molecules related to the migration of immune cells, adhesion, inflammatory responses, regulation of T cell proliferation and chemotaxis, as shown by whole-genome microarray and gene-ontology (GO) analysis ( Fig. 2a -c). A heat map of the 20 most-affected transcripts showed that 5B8 inhibited the fibrin-induced transcription of a group of genes encoding molecules that regulate innate and/or adaptive immune responses (Fig. 2c ). The reduction in the expression of Ccl24, Tnfs18, Il12b, Cxcl3 and Ifng (which encode proinflammatory molecules) by 5B8 was confirmed by quantitative RT-PCR ( Fig. 2d ). 5B8 did not affect the LPS-induced expression of genes encoding proinflammatory molecules ( Fig. 2e ), which suggested that the suppression of the activation of innate immunity by 5B8 might have been selective for fibrin. Furthermore, 5B8 or its F(ab) fragment alone inhibited microglial activation and the expression of chemokine-encoding genes in fibrinogen-induced encephalomyelitis ( Supplementary  Fig. 3) , an acute neuroinflammatory model that results from fibrininduced microglial activation 16 . Thus, we had devised a paradigm for the development of a fibrin epitope-specific immunotherapy. The result was 5B8, a highly selective monoclonal antibody that blocked fibrin-induced, CD11b-mediated activation of innate immunity without affecting fibrin polymerization, in vivo clotting time or aPTT in human plasma.
Fibrin induces NADPH oxidase-mediated neurodegeneration.
A consequence of the activation of innate immunity in CNS autoimmune and neurodegenerative diseases is neurotoxicity; its successful treatment remains a major unmet clinical need. Intriguingly, fibrin induced the expression of several genes encoding molecules that regulate oxidative stress and the release of ROS ( Fig. 3a) and
Articles NATure IMMuNology that are linked to neurotoxicity 7, 21 . Ncf4, which encodes the p40 phox subunit of the NADPH oxidase Nox2 complex, was among the genes most upregulated by fibrin ( Fig. 3a) . NADPH oxidase is a multicomponent enzyme system that is upregulated in human MS 22 and AD 23 . Increased activation of NADPH oxidase and oxidative stress are common mechanisms of neurodegeneration in diseases with fibrin deposition, including MS, AD, stroke, traumatic brain injury and brain aging 6, 24, 25 . Intriguingly, fibrin increased protein expression of the Nox2 component gp91 phox , phosphorylation of p40 phox and NADPH oxidase activity; these increases were all reduced when macrophages were treated with 5B8 ( Fig. 3b,c) . Treatment with 5B8 inhibited the fibrin-induced release of ROS in both mouse macrophages and human macrophages ( Fig. 3d,e ). The fibrin-induced generation of ROS was reduced in BMDMs when the p47 phox subunit of NADPH oxidase was ablated genetically and when NADPH oxidase or CD11b was inhibited by treatment with apocynin or the M1/70 antibody to CD11b, respectively ( Fig. 3f,g and Supplementary Fig. 4a ). In the culture conditions assessed, stimulation with fibrin or treatment with antibodies did not affect BMDM density ( Supplementary Fig. 4b ). In a co-culture of cortical neurons and macrophages, which recapitulates the noncell-autonomous degeneration of CNS neurons, fibrin-primed macrophages induced significant loss of MAP-2 + neurons and increased the fragmentation and blebbing of neurites ( Fig. 3h ). Notably, 5B8 effectively blocked this pathogenic cascade (Fig. 3h ). These results suggested that fibrin caused neurotoxicity via a causal chain that involved CD11b-mediated activation of innate immune cells and increased ROS production by NADPH oxidase.
Fibrin-targeting immunotherapy protects EAE mice from axonal damage. Evidence from human MS has underscored the contributions of fibrin, innate immunity and oxidative stress to the onset 
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Fig. 2 | Changes in gene expression induced by the treatment of fibrin-stimulated
BMDMs with 5B8. a, Whole-genome microarray analysis of BMDMs stimulated for 6 h with fibrin and 5B8 or IgG2b (above plot), presented as an MA plot of the ratio of expression in 5B8-treated BMDMs relative to that in IgG2b-treated BMDMs (log 2 fold values) (M) versus mean average expression of each gene (A), showing genes whose expression was significantly increased (orange) or decreased (purple) by 5B8 or not (gray); horizontal lines indicate no change in expression (middle) or delimit a change in expression of 1-fold to -1-fold. Selected genes among the top 10 downregulated or upregulated are labeled. Data are from three independent experiments. P < 0.001 (two-tailed, raw; moderated t-test). b, GO-Elite analysis of transcripts in BMDMs treated as in a (above plot), identifying the top ten biological processes (left margin) with the most significantly downregulated transcripts in 5B8-treated BMDMs relative to their expression in IgG2b-treated BMDMs (z-score > 2.0; P < 0.05). c, Whole-genome microarray analysis of the expression (key below) of various immunity-related genes (left margin) in BMDMs treated with various combinations (grid above plot) of fibrin, 5B8 and IgG2, identifying the top 20 most significantly downregulated transcripts in fibrin-stimulated BMDMs treated with 5B8. Data are from three independent experiments. Each column represents one sample from each experiement. d, qRT-PCR analysis of transcripts from genes encoding proinflammatory molecules in BMDMs treated as in c (grid below plot), presented as expression in fibrin-stimulated BMDMs treated with 5B8 relative to that in those treated with IgG2b (log 2 fold values). Each symbol represents an individual experiment. Data are from three independent experiments (mean + s.e.m.). **P = 0.0052 (Tnfsf18), 0.0050 (Cxcl3) or 0.0015 (Ifng), and ***P = 0.0001 (Ccl24) or 0.0010 (Il12b) (unpaired two-tailed t-test with Welch's correction). e, qRT-PCR analysis of BMDMs treated with various combinations (grid below plot) of LPS, IgG2b and 5B8, presented as expression in LPS-stimulated BMDMs treated with 5B8 relative to that in those treated with IgG2b (log 2 fold values). Each symbol represents an individual experiment. Data are from three independent experiments (mean + s.e.m.). P values, not significant (unpaired two-tailed t-test with Welch's correction).
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Given prophylactically, 5B8 reduced the mean maximum clinical score and delayed the first day of onset relative to those of groups treated with IgG2b ( Supplementary Tables 1 and 2) . Given therapeutically, 5B8 reduced the severity of relapses in PLP 139-151 EAE ( Fig. 4b and Supplementary Table 1 ). In all EAE treatment groups, 5B8 reduced the proportion of paralyzed mice (Fig. 4c ). Fibrin is a cross-linked polymer of fibrinogen molecules. Consequently, antibodies to fibrinogen detect both fibrinogen and fibrin 11 . Fibrinogen is converted to fibrin at sites of increased coagulation activity 11 . In the spinal cord during EAE, coagulation activity promotes the 
Articles
NATure IMMuNology
conversion of fibrinogen to fibrin, which leads to parenchymal deposition of fibrin at areas of microglial activation and demyelination 27 . After intraperitoneal injection of biotinylated 5B8 into mice with EAE, 5B8 spatially correlated with fibrin(ogen)-rich areas in the spinal cord ( Fig. 4d ), which demonstrated engagement of the target.
To determine whether 5B8 inhibited the recruitment of inflammatory cells into the CNS, we induced EAE in Cx3cr1 GFP/+ Ccr2 RFP/+ mice (in which chemokine receptor CX3CR1 + microglia express green fluorescent protein (GFP), and chemokine receptor CCR2 + macrophages express red fluorescent protein (RFP)) and then 
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NATure IMMuNology treated these mice with 5B8. We found that 5B8 inhibited both the accumulation of CX3CR1 + microglia and the infiltration of CCR2 + monocytes into the CNS in these mice ( Fig. 5 ). Increased NADPH oxidase activity and excessive ROS production have been linked to MS 28 , and ROS generated by invading and resident CNS macrophages mediate demyelination and axonal damage in EAE 7 . 5B8 markedly diminished axonal damage, the generation of ROS, inflammation and demyelination in EAE ( Fig. 5 and Supplementary Fig. 5a,b ). In accordance with published studies 7, 12 , axonal damage correlated with ROS + areas in EAE lesions ( Supplementary Fig. 5c ). The fibrin peptide γ 377-395 inhibits the binding of fibrin to CD11b and suppresses EAE without affecting peripheral T cell responses 13 . Similarly, 5B8 did not significantly alter peripheral T cell responses in mice with PLP 139-151 EAE (CD4 + T cells, P = 0.8413; CD8 + T cells, P = 0.4048 (two-tailed Mann Whitney test); Supplementary Fig. 6 ), which suggested that 5B8 did not modulate peripheral adaptive immune responses. These results suggested that systemic delivery of 5B8 in vivo was well tolerated and that fibrin-targeting immunotherapy suppressed the activation of innate immunity, oxidative stress, demyelination and axonal damage in EAE.
Fibrin-targeting immunotherapy protects mice with AD.
Neurodegeneration driven by the innate immune system has emerged as a key pathogenic mechanism in AD 5 . We therefore investigated whether blocking fibrin-CD11b interactions protected mice against amyloid-related neurodegeneration. In 5XFAD mice (in which transgenes encoding familial AD mutant forms of human amyloid precursor protein and presenilin 1 are expressed in neurons), fibrin was detected in the brain as early as 3 months of age; at 5 months, fibrin accumulation was abundant at sites of amyloid-β (Aβ ) deposition, which were surrounded by CD11b + microglia ( Fig. 6a and Supplementary Fig. 7a ). Also in accordance with prior findings in TgCRND8 mice (which overexpress human amyloid precursor protein) 29 , fibrin deposits were detected in 5XFAD mice in the vicinity of dystrophic neurites (Fig. 6b ), a key feature of neurodegeneration in AD 30 . Systemically administered 5B8 spatially correlated with fibrin-rich areas surrounding Aβ plaques in 5XFAD mice ( Fig. 6c and Supplementary Fig. 7b ), which demonstrated penetration of the brain and engagement of the target.
To determine whether blocking fibrin-CD11b interactions protected mice against amyloid-related neurodegeneration, we treated 5XFAD mice with 5B8 for 2 months, starting at 3.5 months of age (1.5 months after the appearance of Aβ plaques and microglial activation) ( Fig. 7a ). Treatment with 5B8 reduced the loss of cholinergic neurons and microglial activation around plaques in 5XFAD mice (Fig. 7b ,c) without significantly affecting Aβ plaques or the number of MAC-2 + macrophages around plaques (P = 0.1142 (two-tailed Mann-Whitney test); Supplementary Fig. 8a,b ). Whole-genome microarray and GO analysis of cortical gene expression in 5XFAD mice showed that 5B8 suppressed five key pathways: the complement pathway, antigen presentation, cytokine response, lysozyme and ROS (Fig. 7d ). Overall, these findings suggested that blocking fibrin-CD11b signaling suppressed amyloid-induced neurodegeneration and reduced the expression of genes encoding molecules that promote inflammation and oxidative stress. 
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Fibrin-targeting immunotherapy suppresses genes of the TYROBP network. Gene-network analysis has broadened the understanding of AD pathogenesis by revealing immunological gene networks as probable causal contributors to AD pathology 31 .
Targeting these networks could culminate in the development of novel therapeutics. To identify gene networks that might be regulated by 5B8, we investigated our transcriptomics data by biological network analysis. First, we performed genetic network modeling 
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NATure IMMuNology of genes downregulated by 5B8. Co-expression analysis revealed 5B8-downregulated genes to be densely interconnected encoding molecules mainly of the complement pathway, including C4b and C1q, with Tyrobp (which encodes the adaptor DAP12) forming a major hub (Fig. 8a) . The cluster of co-expressed genes downregulated by 5B8 showed a striking overlap with networks of genes encoding molecules linked to the pathogenesis of human AD, including those encoding the TYROBP-related microglial module 31 . Indeed, Tyrobp, which encodes a co-receptor for CD11b and the human AD-associated receptor Trem2, was one of the genes with the greatest degree of downregulation by 5B8 ( Figs. 7d and 8a) . Overlay of gene-expression data obtained from 5B8-treated 5XFAD mice with networks of genes encoding neuroinflammatory molecules from brains of humans with AD showed a reduction in the expression of genes in the human AD-related inflammatory networks by 5B8. By overlaying our data onto a mouse version of the human AD TYROBP module 31 , we found that 5B8 downregulated 65% of the Tyrobp-related network at various levels of significance, including Tyrobp at the nexus of the network (Fig. 8b) . Several components of the TYROBP signaling pathway were also downregulated ( Supplementary Fig. 8c ). This bioinformatics approach allowed us to gain insight into the mechanisms of action of treatment with 5B8, as we identified downregulation mainly of co-expressed genes encoding components of the complement pathway that were relevant to the pathogenesis of AD. Integrated gene network analysis might be a useful tool with which to better understand the mechanism of action of new drugs and assess their efficacy in suppressing inflammatory gene networks relevant to human disease. Thus, the inhibition of fibrin by 5B8 might suppress the pathogenic activation of innate immunological pathways that mediate amyloid-related neurodegeneration.
Discussion
Our study has revealed a previously unknown neurodegenerative pathway in which fibrin activated NADPH oxidase in innate immune cells to promote ROS production and neurotoxicity. By developing an antibody-based approach to selectively target a key inflammatory fibrin domain, we showed here that fibrin-targeting immunotherapy can be selective and efficacious in suppressing neuroinflammation and neurodegeneration. Consequently, preventing fibrin from engaging this mechanism might lead to the development of therapeutic strategies for the treatment of neurodegenerative diseases with neurovascular dysfunction. This discovery might have implications beyond the CNS, since fibrin deposition is a common thread in inflammatory pathologies, such as rheumatoid arthritis, colitis and Duchenne muscular dystrophy (reviewed in refs 11, 12 ). Fibrin-CD11b signaling induces chemokine release and macrophage recruitment 16 and increased activation of NADPH oxidase, which culminates in the release of ROS and oxidative stress (as we have shown here). Therefore, inhibitors of the fibrin-CD11b interaction, such as 5B8, have the potential to affect both inflammatory processes and oxidative stress. Inhibiting the formation of fibrin with anticoagulants can cause adverse effects by increasing the risk of bleeding 32 . Epitope-selective targeting of fibrin might overcome that challenge through selective suppression of its damaging functions without adverse anticoagulant effects. Overall, fibrintargeting immunotherapy might represent a selective multi-indication therapy for the suppression of fibrin-induced chronic inflammation 
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Our study has revealed a previously unknown function for fibrin-CD11b signaling as an activator of NADPH oxidase-dependent production of ROS. CD11b-dependent respiratory bursts require signaling via DAP12 33 . CD11b and DAP12 are co-expressed in microglia and act synergistically to promote the production of superoxide ions and induce neuronal death 33 . Intriguingly, DAP12 was a major pathway downregulated by fibrin-targeting immunotherapy in the 5XFAD mouse brain. Fibrin (via activation of CD11b-CD18 signaling) might increase DAP12 expression and potentiate oxidative damage dependent on CD11b-DAP12 by promoting phosphorylation and assembly of the NADPH oxidase complex 34, 35 and activating kinase pathways 13 . In addition to fibrin, several other immunologically mediated mechanisms can activate NADPH oxidase, such as the binding of Aβ to the scavenger receptor CD36 or the activation of CD11b-CD18 or receptor TLR4 signaling by α -synuclein or LPS 25 . Aβ -induced activation of NADPH oxidase in innate immune cells contributes to neurovascular dysfunction, neurodegeneration and cognitive decline in mice with AD 5, 36 . Fibrin and Aβ might have an additive effect on the activation of NADPH oxidase via CD11b-CD18 and CD36, respectively. Genome-wide association studies, converged linkage analysis and gene-expression data have indicated immunological regulation of AD pathology. Such studies, in combination with the limited success of clinical trials in which amyloid is targeted, have led to a reassessment of the pathogenesis of AD and the need for the development of new treatments directed against different targets 37 . Vascular pathologies and amyloid pathologies are independent and additive predictors of cognitive decline in the elderly 38, 39 , which suggests that they might need to be targeted independently for maximal therapeutic benefit. Fibrin-targeting immunotherapy did not reduce the deposition of Aβ after 2 months of administration, which would suggest that its neuroprotective effects occur in the presence of Aβ . Future studies should determine whether 5B8 also affects cognitive performance in mice with AD.
Fibrin-targeting immunotherapy represents a novel approach with which to selectively suppress pathogenic innate immune responses with potential clinical implications. In MS, anti-inflammatory medications have little effect during the progressive phase of disease, which is mediated by innate immunological mechanisms 3, 8 . Other modulators of innate immunity, such as complement, CR3, TNF, NF-κ B, PI3K and TLR4, are ubiquitously expressed in the brain and the periphery and have reported roles in regulating physiological CNS functions. In contrast, fibrin is not present in the normal brain but is abundantly deposited in the CNS after disruption of the BBB 11 . 5B8 was selective in inhibiting the activation of innate immunity via targeting fibrin and did not affect the activation of macrophages by other ligands, such as LPS, which suggested that the activation of innate immunity by other ligand-receptor interactions could proceed normally. Phagocytic pathways in innate 
NATure IMMuNology immune cells are required for the clearance of debris and remyelination 40 . Fibrin-primed macrophages inhibit the differentiation of oligodendrocyte precursor cells 41 , which are susceptible to oxidative stress 42 . Fibrin-targeting immunotherapy could suppress fibrininduced chronic inflammation and potentially promote repair by inhibiting oxidative stress and the release of proinflammatory factors. Microglia and macrophages are functionally distinct populations with diverse functions in neurodegenerative diseases [43] [44] [45] [46] . Studies using mass cytometry and large transcriptomics profiling of microglia and macrophages will be needed to determine the potential differential effects of fibrin on innate immune cell populations. The inflammatory epitope γ 377-395 of fibrin has been confirmed genetically in inflammatory models in the brain and periphery with findings replicated in numerous laboratories (reviewed in refs 11, 12 ). It is possible that pharmacological targeting of fibrin might represent a selective treatment to add to the toolbox of therapies directed against innate immunity that might be particularly efficacious for suppressing neuroinflammation at sites of BBB leakage and vascular damage with fibrin deposition. The genetic and pharmacological tools available for studying the epitope γ 377-395 (Fgg 390-396A mice, which express a γ 390-396A mutant fibrinogen γ -chain; the γ 377-395 peptide; and antibody 5B8 in our study here) have revealed mainly pathogenic functions for the epitope γ 377-395 in inflammation. Fga -/mice, which lack fibrinogen, and Fgg 390-396A mice 13, 47, 48 , as well as mice treated with 5B8 (as in our study here), with γ 377-395 peptide 13 or with anticoagulants 13, 26, 41 , are not immunocompromised and can be housed in conventional animal facilities without opportunistic infections. In humans, congenital afibrinogenemia, a genetic disorder characterized by a complete absence of fibrinogen, is associated with excessive bleeding but no increase in opportunistic infections 49 . Fibrin inhibits repair, as persistent deposition of fibrin inhibits wound healing 50 , while depletion of fibrin increases remyelination 41, 51 . Such studies do not exclude the possibility that the fibrinogen epitope γ 377-395 might have physiological functions that have not yet become apparent through the use of the genetic and pharmacologic tools available. Collectively, prior genetic studies of the γ 377-395 epitope and our findings here support the proposal that fibrin induces, in a ligandselective manner, a specific gene signature in immune cells that produces mainly pathogenic functions. Consequently, targeting fibrin-induced activation of innate immunity has the potential to suppress proinflammatory and neurotoxic pathways without substantial interference with protective functions of the innate immune system. Immunotoxicology studies will also be needed in the future to fully test potential immunological dysfunction in the context of fibrin-targeting immunotherapy.
Fibrinogen is a coagulation factor essential for blood clotting. Studies of Fgg 390-396A mice have shown that the epitope γ 377-395 is not required for fibrin polymerization or platelet aggregation and does not increase bleeding risk 48 . Fgg 390-396A mice have normal concentrations of fibrinogen, fibrin polymerization and platelet aggregation, normal thrombus formation in FeCl 3 -injured carotid arteries, and normal pregnancy and birth rates. Furthermore, they do not develop spontaneous hemorrhagic events and tolerate major surgical procedures (such as abdominal surgeries) without inordinate bleeding 48 . In contrast to Fgg 390-396A mice, Fga -/mice, which lack fibrinogen exhibit broad hemostatic abnormalities secondary to the lack of clotting function and failure of fibrinogen-supported platelet aggregation and uniformly cannot sustain pregnancy due to the hemostatic requirements at the placental-maternal interface 47 , a phenotype also observed in mice that lack the transglutaminase fXIIIA 52 . Consistent with experimental findings for Fgg 390-396A mice, the fibrin peptide γ 377-395 does not inhibit normal clotting time in vivo or fibrin polymerization in vitro 13 . Our study has shown that 5B8 did not affect normal clotting time in vivo, fibrin polymerization in vitro or aPTT in human plasma. Similar to Fgg 390-396A mice, mice treated with 5B8 even for prolonged periods of up to ~2 months did not develop any spontaneous bleeding. The γ 377-395 epitope targeted by 5B8 does not overlap with the γ 398-406 residues known to be enzymatically cross-linked by fXIII 53 . Nevertheless, comparative studies of fXIII-mediated crosslinking in vitro and in vivo will be of interest in future studies of 5B8. This could be of particular interest in light of studies of Fgg 390-396A mice in a model of venous thrombosis 54 . In those studies, Fgg 390-396A mice were shown to maintain fXIII-mediated cross-linking of the γ -chain but at a reduced rate, and this resulted in smaller venous thrombi. Overall, studies of Fgg 390-396A mice 48 , data obtained with the fibrin peptide γ 377-395 (ref. 13 ) and our results in this study suggest that the epitope γ 377-395 and 5B8 do not interfere with fibrin clotting and present a limited risk of spontaneous hemorrhagic events. Additional toxicology studies will be needed to determine whether 5B8 interferes with other features of hemostasis and thrombosis.
Together, data from human pathology, genetic and pharmacological studies of mice, transcriptomics and signal-transduction studies have established fibrin as a dual inflammatory and oxidative-stress signal in the CNS and suggest that fibrin-targeting immunotherapy might prevent neurodegeneration and other complications in conditions associated with fibrin deposits at sites of disruption of the BBB. Fibrin-targeting immunotherapy might hold promise as a new therapeutic strategy for neurological and inflammatory disorders with vascular damage.
online content
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41590-018-0232-x.
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Methods Animals. SJL/J mice, C57BL/6 mice, Cx3cr1 GFP/+ mice 55 , Thy1-YFP mice (Tg(Thy1-YFP)HJrs) 56 , 5XFAD mice (B6SJL-Tg (APPSwFlLon,PSEN1*M146L*L286V) 6799 Vas/Mmjax) 57 ,and mice with genetic ablation of p47 phox (ref. 58 ) were purchased from The Jackson Laboratory, and Sprague-Dawley rat P 0 litters were purchased from Charles River Laboratories. 5XFAD mice were crossed with Thy1-YFP mice to generate 5XFAD:Thy1-YFP mice. Ccr2 RFP/RFP mice on a C57BL/6 background (provided by I.F. Charo (Gladstone Institutes)) were bred to generate Cx3cr1 GFP/+ Ccr2 RFP/+ mice 59 . Mice were housed in groups of five under standard vivarium conditions and a 12 h light-12 h dark cycle. All animal protocols were approved by the Committee of Animal Research at the University of California, San Francisco, and were in accordance with the National Institutes of Health guidelines.
Mouse monoclonal antibody production. The synthesis of human fibrinogen peptides γ 190-202 and γ 377-395 and production of mouse monoclonal antibodies were performed by A&G Pharmaceuticals. Screening of 480 hybridomas was performed by ELISA against peptides or the carrier protein. Positive clones were expanded and re-tested to confirm peptide epitope reactivity to either γ 190-202 or γ 377-395 . Target candidates were identified as outlined in Supplementary Fig. 1a . The structural map of the γ C domain of fibrinogen was generated using the PyMOL Molecular Graphics System, version 1.6 (Schrödinger) with PDB accession code 1FIC.
Peptide-binding assays. Human peptide γ 377-395 (Genscript) in carbonate buffer (0.1 M NaHCO 3 and 0.15 M NaCl) was coated onto MaxiSorp ELISA plates (Thermo Fisher Scientific) overnight at 4 °C. Wells were incubated with blocking buffer (3% bovine serum albumin (BSA) and 0.1% NP-40 in PBS) for 2 h at 25 °C, washed with 0.05% Tween-20 in PBS. Antibodies 5B8, 4F1, 4E11 and 1E3 were diluted in blocking buffer and were added to the wells for 2 h at 25 °C, followed by secondary polyclonal goat anti-mouse IgG/HRP (#P0447, DAKO) in blocking buffer for 2 h at 25 °C and results were developed with TMB substrate (Sigma-Aldrich) with absorbance at 450 nm measured with an Envision Microplate reader (Perkin Elmer). For competition ELISA, antibody 5B8 was diluted to 2 nM in blocking buffer and was pre-incubated with increasing concentrations of human or mouse peptide γ 377-395 and γ 190-202 for 3 h at 25 °C. Competition of 5B8 with γ 377-395 or γ 190-202 was assessed by incubation on plates coated with human peptide γ 377-395 .
Fibrin or fibrinogen binding. Human plasminogen-free fibrinogen (#341578, EMD Millipore) was depleted of IgG with a Pierce albumin/IgG removal kit (Thermo Fisher Scientific). IgG-depleted human plasminogen-free fibrinogen (25 µ g/ml) in 20 mM HEPES buffer, pH 7.4, was treated with 0.3 U/ml bovine thrombin (Sigma-Aldrich) and 7 mM CaCl 2 in MaxiSorp ELISA plates (Thermo Fisher Scientific) for 1.5 h at 37 °C. Formed fibrin was dried onto the wells at 37 °C overnight. IgG-depleted human fibrinogen (25 µ g/ml) was coated onto the wells at 37 °C for 2.5 h. Plates were washed with binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA and 0.05% Tween-20) and were incubated with blocking buffer (binding buffer containing 3% BSA) for 1 h at 25 °C. Monoclonal antibodies in blocking buffer were incubated for 1 h at 25 °C. Following washing with binding buffer, polyclonal goat anti-mouse IgG/HRP (#P0447, DAKO) in blocking buffer was added for 1 h at 25 °C, and the signal was developed with Lumi-Phos HRP (Lumigen) and measured with an Envision Microplate reader. Experiments of antibody binding to peptides, fibrin and fibrinogen performed at the Gladstone Institutes were independently reproduced at the UCSF Small Molecule Discovery Center and at Lundbeck, US with similar results.
CD11b I-domain production. Plasmid pET15-His-TEV-CD11b was constructed by cloning of the CD11b I-domain (residues Q130-S326) into a pET15b-derived plasmid at the NdeI and XhoI sites, preceded by an N-terminal 6xHis tag and followed by a TEV protease cleavage site (pET15-His-TEV-CD11b), then was transformed into Rosetta2(DE3) cells. Protein was expressed and purified as described 60 , with the exception that cells were lysed by a pressure-driven microfluidizer, and His-containing proteins were trapped using TALON cobalt affinity resin. Protein purity was assessed to be > 90% by LC-MS and gel electrophoresis.
CD11b I-domain ELISA. 96-well ELISA plates (Greiner) were coated with 25 µ g/ml fibrin or fibrinogen and were incubated in blocking buffer as indicated for binding assays for 1 h before the addition of 50 µ l per well of biotinylated CD11b I-domain in PBS with 0.5% BSA and 0.05% Tween-20 for 2 h at 37 °C, followed by incubation with 1 µ g/ml HRP-coupled streptavidin (BD Pharmingen, 1:1,000) for 1 h at 25 °C and were developed by incubation with TMB/E substrate (Chemicon-Millipore), and absorbance was measured at 450 nm with a Synergy H4 plate reader (BioTek). For 5B8 competition ELISA, after incubation in blocking buffer, 5B8 was diluted at twofold concentrations from 0.02 µ M to 10 µ M and was incubated for 2 h at 37 °C, followed by incubation of 6.88 µ M CD11b I-domain for 2 h at 25 °C.
Cell culture. Primary microglia and BMDMs were isolated, cultured and treated with fibrin or LPS as previously described 16 . PBMCs (AllCells) (2 × 10 6 cells/ml) were plated in RPMI-1640 medium supplemented with 10% heat-inactivated FBS, 1% penicillin-streptomycin and 50 ng/ml human M-CSF (#300-25, Peprotech) in tissue-culture-treated dishes (Corning). After 24 h, non-adherent cells were removed, and adherent cells were cultivated for an additional 7-8 d at 37 °C in 5% CO 2 .
Morphometry. Primary microglia were stimulated with fibrin for 48 h as described 16 . Microglia were fixed with 4% PFA, permeabilized with 0.1% Triton X-100 and immunostained with FITC-labeled Isolectin B4 (1:300; Sigma-Aldrich) and/or CellMask Red Stain (Thermo Scientific). Blocking involved pre-incubation with 80 µ g/ml antibodies or mouse IgG2b (clone MPC-11, BioXCell BE0086, distributed by the UCSF Monoclonal Antibody Core, endotoxin concentrations < 0.002 EU/µ g) or IgG2b (eBiosciences, endotoxin level < 0.01 EU/µ g) for 2 h at 37 °C before plating of cells for a final concentration of antibodies at 40 µ g/ml. For manual analysis, images were collected using an Axioplan 2 Zeiss microscope with an Axiocam HRc camera and analyzed using ImageJ. 250 cells per condition were counted for each experiment. Activated microglia were classified on the basis of a surface area of > 2,000 μ m 2 . For automated image acquisition and analysis, images of microglia cells were acquired with the GEHC IN-Cell Analyzer 2000, using a 10× lens and excitation/emission filter pairs of 350 nm/455 nm (CellMask Red Stain) and 579 nm/624 nm (Hoechst dye). Images were analyzed with the GEHC IN-Cell Developer Toolbox version 1.9. The Hoechst-stained nuclei were segmented using a 'nuclear' segmentation type, with a set minimum target area of 30 μ m 2 and a set sensitivity of 75%. To minimize artifacts, segmentation with less than 120 intensity units or area greater than 1,000 μ m 2 were excluded. The CellMask Red-stained whole microglia cells were segmented using an 'intensity' segmentation type, with a set threshold between 200 intensity units and 4095 intensity units. The borders of adjacent contacting cells were resolved using the 'clump breaking' segmentation post-processing, which utilizes discrete nuclei as seeds. For segmentation by size, cells > 800 μ m 2 were classified as activated microglia. Only cells containing a nucleus within the cell body area were accepted. All segmented nuclei and cells were then recorded as individual counts.
Fibrin polymerization assay. Human fibrinogen was diluted to 0.15 mg/ml in 20 mM HEPES (pH 7.4) containing 0.15 M NaCl and 5 mM ε -amino caproic acid and was combined with 0.3 U/ml thrombin (Sigma-Aldrich), and 10 mM CaCl 2 . Antibodies (50 µ g/ml) or GPRP peptide (Bachem) were incubated with fibrinogen for 2 h at 37 °C before mixture with CaCl 2 -thrombin. Absorbance at 350 nm over intervals of 60 s was measured using a SpectraMax M5 microplate reader (Molecular Devices) with SoftMax Pro 5.2 software (Phoenix Technologies).
Plasma clotting time and aPTT assay. Plasma-clotting times were measured as described 13 by combination of equal volumes of citrated plasma and 2 U/ml bovine thrombin (Enzyme Research Laboratories) and 40 mM CaCl 2 at 37 °C. The aPTT assay was performed with pooled normal human plasma (Innovative Research) using 50 µ g/ml 5B8 or IgG2b or 0.5 mM GPRP peptide (Bachem). Plasma was incubated with 5B8 or IgG2b at 37 °C for 2 h Clotting was initiated by aPTT-XL (Ellagic acid activator) and 0.02 M CaCl 2 (Thermo Fisher Scientific) and was monitored at 405 nm in a SpectraMax M5 microplate reader.
Real time qPCR, multi-plex qPCR and microarray analysis. RNA isolation, real-time PCR and microarray analysis were performed as described 16 . Primers are listed in Supplementary Table 3 . Microarray data from GEO accession code GSE71084 were used to select ROS-encoding genes with significant expression (log 2 values) to generate heat maps for primary microglia and BMDMs. For multiplex qPCR, primary microglia were plated in 96-well black μ -clear-bottomed microtiter plates (Greiner Bio-One) in DMEM, 10% FBS, 1% penicillinstreptomycin and were allowed to adhere for 24 h before being treated for 4 h with 1 µ M fibrin d-dimer (HyTest) as described 12 . 5B8 or IgG2b (each 20 µ g/ml) was pre-incubated with fibrin d-dimer in DMEM for 3 h at 37 °C before cell treatment. Gene expression was assessed using the RT2 Profiler PCR Array (Rat Inflammatory & Autoimmunity; Qiagen), and only differentially expressed genes (a difference in expression of over twofold; P < 0.05) were reported as the 'mean fold change' . Experiments analyzing the inhibition of gene expression by antibodies performed at the Gladstone Institutes were independently reproduced at Lundbeck, US with similar results.
Oxidant detection with DHE. BMDMs or PBMCs were incubated in RPMI containing 5 µ M DHE (Invitrogen) for 30 min. 100,000 cells/well were plated on 96-well black μ -clear-bottomed microtiter plates (Greiner Bio-One) pre-coated with 25 µ g/ml fibrin. 5B8 or IgG2b (each 20 μ g/ml) (UCSF Monoclonal Antibody Core clone LTF-2) was added in fibrin-coated wells 2 h before plating of cells. BMDMs were incubated with 300 μ M apocynin (Calbiochem) for 1 h or 5 μ g/ ml of anti-CD11b (M1/70, eBioscience) for 30 min before plating. Cells were incubated on fibrin for 24-48 h and were fixed with 4% PFA for 10 min, and DHE fluorescence was detected at 518 nm/605 nm using a SpectraMax M5 microplate reader. Cells were quantified by DAPI counterstaining. In mice, in vivo administration of DHE and detection were performed as described 15 .
NADPH-oxidase activity. BMDMs were plated on 25 µ g/ml fibrin-coated sixwell plates (Greiner Bio-One). 5B8 or IgG2b (each 20 µ g/ml) was added to the Flow cytometry. Primary mouse splenocytes were isolated from 5B8-or IgG2btreated mice 10 d after immunization with PLP 139-151 . Cell suspensions were stained with combinations of antibodies to the following: CD45 (BioLegend clone 30-F11), CD3 (BioLegend clone 17A2), CD4 (BioLegend clone GK1.5), CD11b (BioLegend clone M1/70), B220 (BD Bioscience clone RA3-6B2), Ly6G (eBioscience clone RB6-8C5) and CD11c (BioLegend clone N418). For cytokine analysis, cells were incubated for 4 h with Cell Activation Cocktail (BioLegend), and surfaces were stained for CD3, CD4 and CD8 (BioLegend clone 53-6.7). Cells were then fixed with Cytofix/Cytoperm solution (BD Biosciences), and intracellular cytokine staining was performed with anti-IFN-γ (BioLegend clone XMG1.2) and anti-IL-17-FITC (BioLegend clone TC11-18H10.1). All antibodies were used at 1:300. Flow cytometry was performed on an LSR II (BD Biosciences). Data were analyzed using FlowJo (Tree Star).
Stereotactic fibrinogen injection and drug treatment. Stereotactic injection of fibrinogen into the corpus callosum of Cx3cr1 GFP/+ or C57BL/6 mice and analysis were performed as described 15, 16 . 5B8, 5B8-F(ab) fragment or isotype-matched control antibody IgG2b (clone MPC-11, eBioscience) was injected (10 µ g at 0.2 µ l/min) into the cerebral ventricle (AP, − 2.0 mm; ML, 0 mm; DV, − 2.0 mm) with a 10 µ l syringe attached to a 33-gauge needle 30 min before fibrinogen injection.
5B8 penetration in the CNS and target engagement. Mice were given intraperitoneal injection of 800 µ g/mouse of biotinylated 5B8 every 2 d (three total doses). Mice were perfused with saline, and the spinal cord or brain was processed for fresh frozen sections as described 13 . Sections were fixed with 4% PFA for 10 min, and biotinylated 5B8 was detected using Cy3-conjugated streptavidin (1:100; Invitrogen) for 30 min at 25 °C. Sections were incubated for 1 h with antibody to fibrinogen (1:2,000), followed by FITC donkey anti-rabbit (1:500; Jackson ImmunoResearch) for 30 min at 25 °C. For amyloid plaque staining, sections were counterstained with Methoxy-X04 (Tocris; 4% vol of 10 mg/ml). Two-photon in vivo imaging. Thy1-YFP and Thy1-YFP:5XFAD mice were given intravenous injection of Alexa594-conjugated fibrinogen (Invitrogen) daily for 3 d as described 15 . Mice were also given intraperitoneal injection of Methoxy-X04 24 h before imaging. Methoxy-X04 was solubilized with DMSO-propylene glycol-PBS pH 7.5 (ratio, 2:9:9) at 5 mg/ml. On the day of imaging, a small craniotomy was made, and a custom-made metal plate was affixed to a stage to stabilize the skull. Alexa594-fibrinogen solution was injected retro-orbitally before imaging. The anesthetized animal was placed on a heated pad under an Ultima-IV multiphoton microscope (Prairie) equipped with MaiTai DeepSee-eHP lasers (Spectra Physics). The excitation wavelength was 820 nm to simultaneously visualize fibrinogen, methoxy-X04 and YFP dendrites. Imaging was performed from 20 to 150 µ m below the dura, using a Nikon 40× and 0.8 NA immersion lenses with a 1.0 μ m z-step. z-stacks of images were projected along the z-axis to recreate twodimensional representations of the 3D structures within the imaged volumes. Images were adjusted for brightness, contrast and background noise with ImageJ. Spectral unmixing plugin in ImageJ was used to separate overlapping signals.
Network analyses. The TYROBP network and the Microglia Pathogen Phagocytosis Pathway were 'translated' from human-specific, static figures to mouse-specific data models using WikiPathways 63 and HomoloGene. The coexpression network was constructed by extraction of the dominant cluster of downregulated genes of interest (selected from those with change in expression of -0.5-fold or less (log 2 values)and raw P value of < 0.05) on the basids of coexpression interaction data provided by GeneMANIA 64 . Subsequent network visualization, layout, data overlays and subnetwork extraction were performed in Cytoscape 65 . A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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Data collection
Fibrin clotting was traced by measuring absorbance at 350nm over intervals of 60 s using a SpectraMax M5 microplate reader (Molecular Devices) with SoftMax Pro 5.2 software (Phoenix Technologies Ltd.). qPCR data were collected on the StepOnePlus™ Real-Time PCR System (ThermoFisher Scientific). Flow cytometry data were acquired on a BD LSRII (BD Bioscienves) with BD FACSDiva™ software. Confocal microscopy images were taken using a Fluoview FV1000 (Olympus) confocal microscope and FluoView Software. Immunohistochemical microscopy images were collected on an Axioplan II epifluorescence microscope (Zeiss). Two-photon in vivo imaging data were acquired on an Ultima-IV multiphoton microscope (Prairie) equipped with MaiTai DeeSee-eHP lasers (Spectra Physcics). The PyMOL Molecular Graphics System, Version 1.6 Schrödinger, LLC was used for the structural map of the γC-domain of fibrinogen.
Data analysis
GraphPad Prism software v7.03 (GraphPad Software, Inc.) was used to prepare graphs and to perform statistical analyses. Automated Image acquisition and Analysis: Images of microglia cells were acquired with the GEHC IN-Cell Analyzer 2000™and analyzed with the GEHC IN-Cell Developer Toolbox version 1.9. Multiplex qPCR for primary rat microglia: Array analysis was performed with the online RT2 Profiler Data Analysis Software following manufactures default setting (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Fold change was calculated based on the comparative delta delta Ct method and statistical significance was determined by Student's ttest. Deferentially expressed genes were deemed when fold change was >2 and p<0.05. Flow cytometry data were analyzed using FlowJo software (Tree Star, Inc.). MAP-2+ neurite area was quantified with the NeurphologyJ software plug-in to skeletonize the entire well images. Resulting images were thresholded and area was measured with NIH ImageJ analysis software (v1.50). Fluorescent images of primary neurons expressing RFP were thresholded and the degree of fragmentation (number of fragments) was analyzed using the ImageJ plugin 'Analyze Particles.' The statistical test for the differential expression that informed the network figure data overlays: Linear April 2018 models were fitted for each gene using the Bioconductor 'limma' package in R. Moderated t-statistics, fold change and the associated P values were calculated for each gene. The coexpression network was constructed by extracting the dominant cluster of downregulated genes of interest (selected from those with log2 fold change of -0.5 or less and raw p-value < 0.05) based on coexpression interaction data provided by GeneMANIA. Subsequent network visualization, layout, data overlays and subnetwork extraction were performed in Cytoscape. Two classes of statistical tests were used to test for differences in the variation of clinical scores and time of onset in the four EAE models between treatment groups. To compare EAE clinical scores, the linear mixed effects models were first performed using the R statistical package. The comparison of means of maximum clinical scores was performed using a two-sample t-test as implemented in R using the Welch's t-test and the Wilcoxon rank sum test. P-values were corrected for multiple testing using the Holm procedure. The statistical significance of the changes in the mean clinical score for each day of the experiment was estimated using permutation tests. The corresponding p-values were estimated using 1000 permutations in all prophylactic antibody treatment and 10000 permutations for therapeutic antibody treatment. In each permutation, mice were randomly permuted. To compare the first day of onset, the log-rank test was used as implemented by the survdiff function in the survival package in R.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability GEO data supporting the findings of this study have been deposited in the GEO depository under accession numbers GSE118920 and GSE118921. The TYROBP network and the Microglia Pathogen Phagocytosis Pathway were translated from human-specific, static figures to mouse-specific data models using WikiPathways and HomoloGene, and are permanently referenced by these links, respectively: http://wikipathways.org/index.php? title=Pathway:WP3625&oldid=85694, http://wikipathways.org/index.php?title=Pathway:WP3626&oldid=85691.
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Sample size
No statistical methods were used to predetermine sample size, but our sample sizes are similar to those reported previously.
Data exclusions
No samples or animals were excluded from the analysis.
For the microglia morphology assay, an exclusion criterion applied was fibrin-induced activation < 20 % compared to control . Experiments with activation > 20% were used for analysis.
Replication
Experiments were replicated several times with reproducible results, as indicated in each figure legend. Fibrin antibody binding to peptides, fibrin, and fibrinogen and gene expression antibody inhibition experiments performed at the Gladstone Institutes were all independently validated at Lundbeck, US with similar results. Fibrin antibody binding studies performed at the Gladstone Institutes were also independently validated at the University of California, San Francisco Small Molecule Discovery Center with similar results.
Randomization Animals were randomly assigned to experimental groups at the beginning of experiments. The randomization of animal studies is stated in the Methods section.
Blinding
For EAE studies and histopathological experiments, the researchers were blinded as to the mouse treatment conditions. Mice were scored by blinded observers. Mice were divided into experimental groups in an unbiased manner. The mice were randomized and coded to assign groups or collect data for animal experiments.
A set of the binding, morphology and fibrin polymerization assays of the monoclonal fibrin antibodies were performed in a blinded manner and the code was unblinded at the end of all three experimental assays.
All imaging of immunohistology and quantification experiments were performed in a blinded manner.
